Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 “multi-points priming” mechanisms in vitro and in vivo

Fig. 3

NCTD inhibits tumor lymphangiogenesis and lymphatic micrometastasis of the in-situ colonic xenografts by western blotting and RT-PCR in vivo. a The expression of CK-20, LYVE-1 and D2-40 proteins in the in-situ colonic xenografts of each group (western blotting): expression of CK-20, LYVE-1 and D2-40 proteins in NCTD, Sorafenib or NCTD + Sorafenib group was decreased significantly as compared to control group (*P < 0.05), with the lowest expression of these proteins in NCTD + Sorafenib group (#P < 0.001). b Fluorescent quantitative RT-PCR: the expression of CK-20, LYVE-1 and D2-40 mRNAs was also decreased significantly in all experimental groups as compared to control group (*P < 0.05); and the expression of CK-20 or LYVE-1 mRNAs in NCTD + Sorafenib group was significantly lower than those of NCTD or Sorafenib group (#P < 0.001)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us